TCM
TYRA icon

TCG Crossover Management’s Tyra Biosciences TYRA Stock Holding History

TCG Crossover Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124M Buy
3,248,980
+350,877
+12% +$11.4M 3.56% 7
2025
Q4 		$76.2M Hold
2,898,103
– – 2.52% 8
2025
Q3 		$40.5M Hold
2,898,103
– – 1.99% 16
2025
Q2 		$27.7M Hold
2,898,103
– – 3.17% 15
2025
Q1 		$27M Buy
2,898,103
+909,000
+46% +$11.8M 3.68% 10
2024
Q4 		$27.6M Hold
1,989,103
– – 2.7% 16
2024
Q3 		$46.8M Hold
1,989,103
– – 3.96% 10
2024
Q2 		$31.8M Hold
1,989,103
– – 3.31% 12
2024
Q1 		$32.6M Hold
1,989,103
– – 2.58% 17
2023
Q4 		$27.5M Hold
1,989,103
– – 3.06% 15
2023
Q3 		$27.4M Hold
1,989,103
– – 4.03% 13
2023
Q2 		$33.9M Hold
1,989,103
– – 5.56% 8
2023
Q1 		$32M Hold
1,989,103
– – 6.23% 5
2022
Q4 		$15.1M Buy
1,989,103
+1,043,396
+110% +$7.38M 2.67% 15
2022
Q3 		$8.31M Buy
945,707
+49,289
+5% +$451K 2.49% 13
2022
Q2 		$6.41M Hold
896,418
– – 2.72% 12
2022
Q1 		$9.59M Buy
896,418
+45,968
+5% +$546K 3.85% 9
2021
Q4 		$12M Buy
+850,450
New +$16.9M 5.6% 8

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TCG Crossover Management's TYRA Position: Q1 2026 in Review

TCG Crossover Management increased its Tyra Biosciences (TYRA) stake by 12% in Q1 2026, buying an estimated $11.4M and bringing the position to 3,248,980 shares worth $124M. The position accounts for 3.56% of the portfolio, ranked #7.

TCG Crossover Management first reported a position in TYRA in Q4 2021 and has held it in 18 quarters since. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • TCG Crossover Management held 3,248,980 shares of Tyra Biosciences worth $124M as of Q1 2026.
  • TCG Crossover Management bought 350,877 Tyra Biosciences shares in Q1 2026, an estimated $11.4M.
  • Tyra Biosciences made up 3.56% of TCG Crossover Management's portfolio in Q1 2026, its #7 holding.
  • TCG Crossover Management first reported a position in Tyra Biosciences in Q4 2021 and has held it in 18 quarters since.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.